Tazeen Ahmad
BofA Securities, Research Division

Welcome to our next session. We've got PTC Therapeutics presenting for the next 30 minutes sitting up here on stage with me are a couple of folks that you definitely would recognize, Matt Klein, who is, of course, Chief Executive Officer; as well as Pierre Gravier, who is Chief Financial Officer. We also have a couple of folks in the audience from the team as well. We might yell out to Eric during Q&A as well. So let's maybe just do a quick overview of the company for the few people who might not know about PTC, Matt, and then we can go into Q&A.

Matthew Klein
CEO & Director

Absolutely. Thank you so much for having us, Tazeen. PTC is a global biopharmaceutical company that discovers, develops and commercializes therapies for diseases of a high unmet need. We have 6 marketed products that we commercialize ourselves around the globe as well as a robust R&D portfolio, including our validated and differentiated small molecule oral splicing platform. We're off to a great start in 2026. We delivered commercial revenue -- total revenue in the first quarter of $273 million with product revenue of $226 million, allowing us to raise guidance for the year. That was really led by our another strong quarter for Sephience, which we launched last year for children and adults with PKU. We did $125 million in revenue globally.

This is a rare disease launch that's leveraging our established global infrastructure. And as I mentioned, we're off to a strong start